Tofacinix is used for long-term treatment. Most people who benefit from this treatment will notice an improvement within four weeks of starting treatment but further improvements can be seen during the first six months of treatment.
Tofacinix is indicated for the treatment of moderate to severe active rheumatoid arthritis adult patients who respond inadequately or are intolerant to methotrexate.
Tofacinix is also used to treat adults with moderate to severe ulcerative colitis. Long-release tofacinix (XR) is not used in the treatment of ulcerative colitis.
Tofacinix may be used as monotherapy or in combination with methotrexate or non-biotic disease-modifying anti-rheumatic drugs (DMARDs).
Tofacitinib is a Janus kinase (JAK) inhibitor. JAK is intracellular signaling enzyme arising from cytokines or growth factor that interacts with receptors on cell membranes that influence the cellular process of hematopoiesis and immune cell function.
In the signaling pathway, JAKs phosphorylate activates transducer signaling and transcription activator (STAT) that modulates intracellular activity including gene expression. Tofacitinib modulates the signaling pathway at the JAK point, blocking phosphorylation and activating STATs. JAK enzymes paired with JAK (ex: JAK1 / JAK3, JAK1 / JAK2, JAK1 / TyK2, JAK2 / JAK2) provide cytokine signaling.
Tofacinix inhibited JAK1 / JAK2 in the in vitro activity of JAK1 / JAK3 and JAK2 / JAK2 combination of enzymes, the 50 microchips of 406.56 and 1377 nM. But specifically, the association of the JAK complex enzyme with the therapeutic effect has not been established.
Contraindicated
Pregnant and lactating women.
Allergic to any ingredients in Tofanix.
Tofacinix 5mg supplemented with Tofacitinib (2)
Dosage and usage Tofacinix
Recommended dosage
Tofacinix can be used in combination with methotrexate or other non-biotic DMARDs
The recommended dose of Tofacitinib is 5 mg twice daily
The recommended dose of Tofacitinib with the Extended-Release Formula (XR) is 11 mg per day.
Switch from Tofacitinib 5mg tablet to Tofacitinib XR 11mg tablet
Patients treated with Tofacitinib 5 mg twice daily may be switched to Tofacitinib 11 mg once daily after their last 5 mg Tofacitinib dose.
If there is a serious infection, decreased blood cells, drug interactions, impaired kidney or liver function, etc., dose adjustment is required.
Using
Tofacinix is used 2 times a day (10mg) for 5mg each.
Tofacinix is taken orally, taken before or after a meal.
Do not break, crush, or chew Tofacinix tablets.
Warnings and precautions when using Tofacinix
Avoid the use of Tofacitinib in patients with severe, aggressive infections including local infections. The risks and benefits of treatment should be considered before starting Tofacitinib in a patient:
Have a chronic or recurrent infection
People exposed to tuberculosis
Have a history of serious or opportunistic infections
People who have resided or traveled in areas of endemic tuberculosis or endemic mycoses
These basic conditions can lead to them becoming infected
Reporting of malignant and lymphoproliferative tumors, malignancies have been observed in clinical studies including not limited to: lung cancer, breast cancer, prostate cancer, and pancreatic cancer .
Gastrointestinal (GI) perforation has been reported, but the role of inhibition of JAK in these events is unclear; patients at risk of gastrointestinal perforation (eg, diverticulitis) should be used. careful.
In connection with a gradual decrease in lymphocyte and neutrophil counts and hemoglobin levels, treatment may be discontinued.
Hyperlipidemia: Treatment with tofacinix may increase blood lipid parameters including: total cholesterol, low density lipoprotein (LDL) cholesterol and high density lipoprotein (HDL) cholesterol.
Not recommended for severe liver damage.
Reports of viral reactivation, including cases of herpes virus reactivation (eg, herpes zoster).
Reporting non-malignant skin cancers (NMSCs), patients with an increased risk of skin cancer should have regular skin tests.
Dosage should be reduced for moderate to severe hepatic impairment or renal impairment.
With caution when treating diabetics, it is common to report that the rate of infection in diabetics is higher.
Side effects of Tofacinix
Systemic infection
Headache
Diarrhea
Nasal congestion, sore throat, and runny nose (rhinitis)
High Blood Pressure
Tell your doctor if you have any of these side effects or do not go away.
Other drug interactions with Tofacinix
Strong CYP3A4 induction may impair the clinical response
If combined with a potent or moderate CYP3A4 inhibitor plus a CYP2C19 inhibitor, an increase in Tofacinix causes a higher risk of side effects, the dose should be reduced.
Avoid use with live virus vaccines
When Tofacitinib is used together with potent immunosuppressants (such as azathioprine, tacrolimus, cyclosporin) increases the risk of immunosuppression. Tofacinix is not recommended with biological DMARD or potent immunosuppressant.
Preservation of Tofacinix
Store the drug in a dry place, away from direct sunlight.
Keep medicine out of reach of children and pets.
Tofacinix 5mg vitamin Tofacitinib thin (4)
Note: Information about the drug Tofacinix 5mg Tofacitinib is for reference purposes only, patients are not allowed to arbitrarily use drugs, all information on drug use must be specified by a specialist doctor.
Nhận xét
Đăng nhận xét